Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWP42003 and GWP42004 in Type 2 Diabetes Dyslipidaemia
NCT01217112Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2010
- Primary completion
- May 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol, tetrahydrocannabivarin in dyslipidemia, type 2 diabetes mellitus (T2DM), sponsored by Jazz Pharmaceuticals plc. Started Oct 2010; status: completed.
02
Drugs
cannabidioltetrahydrocannabivarin
03
Conditions
dyslipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01217112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217112.